# Ligand Pharmaceuticals clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Ligand Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ligand Pharmaceuticals: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/ligand-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2020 | NCT04627831 | Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography | Ligand Pharmaceuticals | Phase 2 | Withdrawn | Contrast-induced Nephropathy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04627831) |
| August 2, 2016 | NCT02851849 | A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus | Ligand Pharmaceuticals | Phase 2 | Completed | Type 2 Diabetes Mellitus | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02851849) |
| February 3, 2016 | NCT02672839 | A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation | Ligand Pharmaceuticals | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02672839) |
| September 26, 2014 | NCT02250222 | Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus | Ligand Pharmaceuticals | Phase 1 | Completed | Type 2 Diabetes Mellitus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02250222) |
| August 9, 2013 | NCT01919684 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2... | Ligand Pharmaceuticals | Phase 1 | Completed | Type 2 Diabetes Mellitus | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01919684) |
| July 17, 2009 | NCT00940953 | Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber... | Ligand Pharmaceuticals | Phase 2 | Completed | Seasonal Allergic Rhinitis | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00940953) |
| July 14, 2009 | NCT00938613 | Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR | Ligand Pharmaceuticals | Phase 2 | Completed | Seasonal Allergic Rhinitis | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00938613) |
| April 9, 2009 | NCT00879112 | Study of MB07811 in Subjects With Hypercholesterolemia | Ligand Pharmaceuticals | Phase 2 | Withdrawn | Hypercholesterolemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00879112) |
| May 7, 2008 | NCT00674453 | The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation | Ligand Pharmaceuticals | Phase 2 | Completed | Bone Loss | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00674453) |
| March 13, 2008 | NCT00635232 | A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension | Ligand Pharmaceuticals | Phase 2 | Completed | Hypertension | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00635232) |
| February 29, 2008 | NCT00626418 | The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome | Ligand Pharmaceuticals | Phase 2 | Completed | Restless Legs Syndrome | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00626418) |
| February 26, 2008 | NCT00623324 | The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease | Ligand Pharmaceuticals | Phase 2 | Completed | Early Stage Parkinson's Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00623324) |
| August 30, 2007 | NCT00522925 | A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension | Ligand Pharmaceuticals | Phase 2 | Completed | Hypertension | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00522925) |
| April 9, 2007 | NCT00458016 | Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus | Ligand Pharmaceuticals | Phase 2 | Completed | Type 2 Diabetes Mellitus | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00458016) |
| September 13, 2005 | NCT00163137 | Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss | Ligand Pharmaceuticals | Phase 3 | Completed | Osteoporosis | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00163137) |
| September 2, 2005 | NCT00143273 | Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation | Ligand Pharmaceuticals | Phase 2 | Completed | Osteoporosis | 497 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00143273) |
| September 1, 2005 | NCT00141323 | Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) | Ligand Pharmaceuticals | Phase 3 | Completed | Osteoporosis | 8,556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00141323) |
| May 25, 2004 | NCT00003752 | Bexarotene in Treating Patients With Metastatic Breast Cancer | Ligand Pharmaceuticals | Phase 2 | Completed | Breast Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00003752) |
| March 25, 2004 | NCT00006345 | Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma | Ligand Pharmaceuticals | Phase 2 | Completed | Drug/Agent Toxicity by Tissue/Organ, Lymphoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00006345) |
| December 5, 2003 | NCT00073736 | Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | Ligand Pharmaceuticals | Phase 1/2 | Completed | Hepatocellular Carcinoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00073736) |
| August 31, 2001 | NCT00002212 | A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma | Ligand Pharmaceuticals | Phase 2 | Completed | Sarcoma, Kaposi, HIV Infections | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002212) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 15 |
| Phase 3 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 5 |
| Osteoporosis | 4 |
| Hypertension | 2 |
| Rhinitis, Allergic, Seasonal | 2 |
| Breast Neoplasms | 1 |
| Sarcoma, Kaposi | 1 |
| HIV Infections | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Restless Legs Syndrome | 1 |
| Drug-Related Side Effects and Adverse Reactions | 1 |
| Lymphoma | 1 |
| Lymphoma, T-Cell, Cutaneous | 1 |
| Mycosis Fungoides | 1 |
| Sezary Syndrome | 1 |
| Bone Diseases, Metabolic | 1 |
| Hypercholesterolemia | 1 |
| Hyperlipidemias | 1 |
| Carcinoma, Hepatocellular | 1 |
| Carcinoma | 1 |
| Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Automotive companies in the United States](https://specstream.ai/data/businesses/automotive-companies/united-states)
- [Health food restaurants in the United States](https://specstream.ai/data/businesses/health-food-restaurants/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
